The millions of people living with obesity need novel treatment options that are safe, effective and avoid the high costs and ...

New research has found that GLP-1 drugs can substantially reduce the risk of obesity-related cancers — and they’re more ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro ...

A woman who lost 55 pounds on Ozempic opens up about the most difficult side effect she faced—and shares simple tips that ...

First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...

Recent research suggests that Ozempic and other GLP-1 receptor agonists, commonly used for weight loss, may offer unexpected ...

You may have heard of "Ozempic face" and "Ozempic butt." Well, now there's "Ozempic mouth" and "Ozempic feet" to describe ...

A new trial involving 17,000 people on weight loss drugs found they reduced the risk of stroke and heart disease by half.

Mounjaro and Ozempic slashed the risk of contracting the disease. Scientists from Israel said the drugs, also known as GLP-1s ...

In Australia, Ozempic is approved for the treatment of type 2 diabetes, while Wegovy is approved for weight management. Both ...

Despite Ozempic being the most recognisable brand name, as far as the people prescribing it are concerned weight loss is ...